Risk of selected gastrointestinal toxicities in cancer patients treated with Pazopanib: a systematic review and meta-analysis

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter L. Abdallah
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors L. Abdallah1, O. Abdel-Rahman2, H. Elhalawani1, M. Heiba1
  • 1Ain Shams University, Cairo, Egypt, /
  • 2Faculty of Medicine - Ain Shams University, Abasseya, Egypt, /

Abstract

Targeting tumor angiogenesis has emerged as the state of the art strategy in treating different types of solid tumors. Tyrosine kinase inhibitors (TKIs) are anti-angiogenic agents targeting vascular endothelial growth factor receptors (VEGFR). Pazopanib is one of the agents in this class, has been approved recently in metastatic soft tissue sarcoma and metastatic renal cell carcinoma. We constructed this meta-analysis of gastrointestinal adverse events associated with Pazopanib use in solid tumors patients. Targeting tumor angiogenesis has emerged as the state of the art strategy in treating different types of solid tumors. Tyrosine kinase inhibitors (TKIs) are anti-angiogenic agents targeting vascular endothelial growth factor receptors (VEGFR) Pazopanib is one of the agents in this class, has been approved recently in metastatic soft tissue sarcoma and metastatic renal cell carcinoma. We constructed this meta-analysis of gastrointestinal adverse events associated with Pazopanib use in solid tumors patients.